Am J Psychiatry 159:133-135, January 2002
© 2002 American Psychiatric Association
Elevation of Prolactin Levels by Atypical Antipsychotics
Peter Turrone, B.A.(Sp.H.), M.Sc.,
Shitij Kapur, M.D., Ph.D., F.R.C.P.C.,
Mary V. Seeman, M.D., F.R.C.P.C., and
Alastair J. Flint, M.D., F.R.C.P.C.
|
Abstract
|
OBJECTIVE: Atypical antipsychotics are thought not to elevate prolactin levels. The authors examined data suggesting that atypical antipsychotics do elevate prolactin levels but more transiently than typical antipsychotics. METHOD: Prolactin levels in 18 male patients with schizophrenia who were receiving atypical antipsychotics were monitored over the 24-hour period following administration of their daily oral dose of risperidone, olanzapine, or clozapine. RESULTS: The baseline prolactin levels in patients receiving risperidone (mean=27 ng/ml, SD=14) were abnormally high, but baseline prolactin levels in patients receiving olanzapine (mean=9 ng/ml, SD=5) and clozapine (mean=9 ng/ml, SD=5) were not high. All three atypical antipsychotics caused a doubling of prolactin levels over baseline levels 6 hours after medication administration. CONCLUSIONS: These data suggest that these atypical antipsychotics raise prolactin levels, although the increases with olanzapine did not reach statistical significance. This suggests that the differences in the effects on prolactin levels of atypical and typical antipsychotics are not categorical but lie in the degree and duration of dose-induced prolactin elevation, attributable to the differential binding properties of each drug on pituitary dopamine D2 receptors.
|
Introduction
|
Clozapine, unlike typical antipsychotics, does not elevate prolactin levels (1). This unique clinical feature led researchers to classify hyperprolactinemia as one of the hallmark features of "atypicality" (2). Newer antipsychotic medications that mirror this profile have been developed (3, 4). Risperidone is the exception in that it does not mirror the profile of clozapine (5).
A major limitation of the clinical studies of the atypical antipsychotics is that data derive from prolactin measurements at a single point in time, usually 12–24 hours after medication administration. There is evidence that atypical antipsychotics have some effect on the prolactin system. For example, it has been demonstrated that the acute administration of clozapine leads to rapid, short-lived prolactin elevation (6).
This study is an attempt to explore whether administration of three commonly prescribed atypical antipsychotics resulted in dose-related transient elevation of prolactin levels in patients with chronically treated schizophrenia.
|
Method
|
The study was approved by the Human Subjects Review Committee of the University of Toronto. Written informed consent was obtained from all participants after the procedures had been fully explained. Male patients with a diagnosis of schizophrenia were included if they were taking either clozapine (at least 300 mg/day), risperidone (1–6 mg/day), or olanzapine (10–20 mg/day); if they had been receiving these medications for more than 8 weeks; and if the prescribed dose had remained the same for at least 1 week.
Patients were excluded from participation if they had been prescribed depot antipsychotics within 6 months of the study; had any physical condition that could affect prolactin levels such as endocrine disorders; or were receiving concomitant antidepressant or antiparkinsonian medication. Other concomitant medications that are not known to affect the prolactin-secreting system were permitted; however, the patients did not take any of these drugs on the day of the study. Subjects were asked to fast and not take their evening antipsychotic medication the night before the study.
On the day of the study, subjects arrived at the hospital at approximately 8:00 a.m. At that time an indwelling intravenous catheter was inserted into the subject’s forearm vein for repeated blood sampling. After 30 minutes, two baseline prolactin samples were obtained 15 minutes apart. Once the second baseline sample was obtained, subjects were instructed to take their medication. Blood samples were then obtained every 60 minutes over an 8-hour period. Subjects returned the next day so that a final blood sample could be obtained at 24 hours.
Blood was centrifuged in glass tubes, and plasma was stored in plastic tubes at –80°C until prolactin assays were completed. Plasma prolactin levels were determined by using microparticle enzyme immunoassay technology with a minimum detectable limit of 0.6 ng/ml and a coefficient of variation of 4.5% (St. Joseph’s Health Centre, London, Ont.). The upper limit of normal for plasma prolactin of 20 ng/ml for men during the waking state was based on sample of 85 healthy male adults (Abbott Laboratories, Abbott Park, Ill.).
Subjects were also given the option of returning and repeating the entire procedure on a separate occasion without taking their antipsychotic medication. This was done so that they could act as their own drug-free control subjects. Five subjects agreed and returned at least 1 month after their initial visit.
|
Results
|
Eighteen male patients with a mean age of 32 years (SD=8) entered the study. Median doses for each drug group were as follows: olanzapine (N=6), 20 mg (range=10–20 mg); risperidone (N=6), 3 mg (range=1–3 mg); clozapine (N=6), 300 mg (range=300–400 mg). The median duration of current antipsychotic treatment was 12 months for patients receiving olanzapine, 36 months for those receiving clozapine, and 8 months for those receiving risperidone.
There was a statistically significant difference in mean baseline plasma prolactin levels among the three medications. The baseline plasma prolactin level of patients receiving risperidone was 27 ng/ml (SD=14), compared with 9 ng/ml (SD=5) for those receiving olanzapine and 9 ng/ml (SD=5) for those receiving olanzapine (F=11.43, df=2, 15, p<0.01). Three of the six patients receiving risperidone were hyperprolactinemic, but the prolactin levels of all patients receiving olanzapine or clozapine were within normal limits.
A repeated measures analysis of variance applying a cubic trend model revealed a significant difference among drugs (F=27.54, df=2, 15, p<0.01), a significant time effect (F=11.62, df=1, 15, p<0.01), and a significant drug-by-time interaction (F=4.90, df=4.88, 36.66, p<0.02) (Figure 1).
View larger version (29K):
[in this window]
[in a new window]
|
Figure 1. Mean Plasma Prolactin Level Changes Over 24 Hours in 18 Patients After Taking Clozapine, Olanzapine, or Risperidone and in Five of the Same Patients After Not Taking the Drugsa
aOne of the patients taking clozapine, two taking olanzapine, and two taking risperidone had their prolactin levels measured twice: first after taking their usual dose of the medication and second, at least 1 month later, after not taking their usual dose.
|
The drug-by-time interaction was explored by using simple effects analysis examining the polynomial contrasts of time at each drug level. This analysis revealed a significant elevation in prolactin level induced by clozapine (F=3.74, df=9, 135, p<0.001) and risperidone (F=6.26, df=9, 135, p<0.001) but not olanzapine (F=1.24, df=9, 135, p>0.05).
There was a statistically significant difference in time to reach peak prolactin levels between risperidone (mean=120 minutes, SD=53), olanzapine (mean=290 minutes, SD=45), and clozapine (mean=180 minutes, SD=53) (F=17.15, df=2, 15, p<0.001).
Within-subject control data were obtained for five patients (one receiving clozapine, two receiving risperidone, and two receiving olanzapine). These patients repeated the procedure of blood draws and prolactin level measurements at least 1 month after their initial visit without taking their usual dose of risperidone, olanzapine, or clozapine. Each patient demonstrated only minor prolactin fluctuations (Figure 1). There was a significant difference for each patient in prolactin levels over the course of 24 hours after taking the medication and after not taking the medication (F=3.51, df=9, 36, p<0.01).
|
Discussion
|
These results indicate that clozapine and risperidone administration results in dose-related elevation in prolactin levels, even after patients have been taking these drugs for a prolonged period of time. Patients receiving olanzapine also showed a near doubling over baseline of prolactin levels, from mean=9 ng/ml (SD=5) to mean=18 ng/ml (SD=10). This difference was not significant, however, presumably because there were only six patients in the group and there was a higher variance in this group. More importantly, our study shows that the increases in prolactin levels with atypical antipsychotics are most pronounced in the 1–5-hour period after medication administration and return to baseline values by 12–24 hours, thus masking the drug’s acute effect on prolactin. Risperidone is the exception to this pattern.
The study is limited by the fact that it was restricted to male patients, the number of patients studied was only 18, standard deviations were large, the patients were not randomly assigned to receive the different drugs, and not every patient participated in the second prolactin measurement after not taking their medication. Nonetheless, we can be reasonably certain about the central conclusion: even atypical antipsychotics give rise to transient drug-specific elevations of prolactin levels, and the difference between typical antipsychotics and atypical antipsychotics has more to do with the degree and duration of prolactin elevation than to a categorical difference.
The precise mechanisms whereby use of atypical antipsychotics leads to a transient effect on pituitary dopamine D2 receptors are unclear. It has been shown that for quetiapine (7), the transient prolactin elevation corresponds to transient dopamine D2 receptor blockade. Whether this is the case for other atypical antipsychotics needs to be confirmed. Further, although the adverse consequences of continuous prolactin elevation are well documented, whether this transient elevation has any clinical implications should be the subject of future investigations.
|
Footnotes
|
Presented as a poster at a meeting of the Society for Biological Psychiatry, Chicago, May 11–13, 2000. Received Nov. 14, 2000; revisions received March 13 and June 13, 2001; accepted July 2, 2001. From the Institute of Medical Science and the Department of Psychiatry, University of Toronto; the Centre for Addiction and Mental Health, Toronto; and Toronto General Hospital. Address reprint requests to Mr. Turrone, Schizophrenia and Continuing Care Program, Centre for Addiction and Mental Health, Clarke Site, 250 College St., Toronto, Ont. M5T 1R8, Canada; peter_turrone{at}camh.net (e-mail). Supported in part by an Ontario Graduate Scholarship, the Frist-Jus Neuropsychopharmacology Scholarship, the Annette Wolfe Award, and the Toronto Rehabilitation Institute Student Scholarship Fund (Mr. Turrone) and by a grant from the Canadian Institute of Health Research and the Canada Research Chairs program (Dr. Kapur). The authors thank Doug Hussey and Kevin Cheung for their technical assistance.
|
References
|
-
Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S: Clozapine: plasma levels and prolactin response. Psychopharmacology (Berl) 1981; 73:184-187[CrossRef][Medline]
-
Meltzer HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989; 99:S18-S27
-
Hamner MB, Arvantis LA, Miller BG, Link CG, Hong WW: Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996; 32:107-110[Medline]
-
Crawford AM, Beasley CM Jr, Tollefson GD: The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26:41-54[CrossRef][Medline]
-
Caracci G, Ananthamoorthy R: Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics (letter). J Clin Psychopharmacol 1999; 19:194-196[Medline]
-
Meltzer HY, Goode D, Schyve PM, Young M, Fang VS: Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979; 136:1550-1555[Abstract/Free Full Text]
-
Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57:553-559[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
C. Manning and T. Stickley
Childhood abuse and psychosis; a critical review of the literature
Journal of Research in Nursing,
November 1, 2009;
14(6):
531 - 547.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T. I. Cremers, J.-M. Rivet, D. Sicard, R. Billiras, and M. Brocco
S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects
J. Pharmacol. Exp. Ther.,
March 1, 2008;
324(3):
1212 - 1226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fitzgerald and T. G Dinan
Prolactin and dopamine: What is the connection? A Review Article
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
12 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Bushe, M. Shaw, and R. C Peveler
A review of the association between antipsychotic use and hyperprolactinaemia
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
46 - 55.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Citrome
Current guidelines and their recommendations for prolactin monitoring in psychosis
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
90 - 97.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee
What Can We Learn from Rodents about Prolactin in Humans?
Endocr. Rev.,
February 1, 2008;
29(1):
1 - 41.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Shim, J.-G. K. Shin, D. L. Kelly, D.-U. Jung, Y.-S. Seo, K.-H. Liu, J.-H. Shon, and R. R. Conley
Adjunctive Treatment With a Dopamine Partial Agonist, Aripiprazole, for Antipsychotic-Induced Hyperprolactinemia: A Placebo-Controlled Trial
Am J Psychiatry,
September 1, 2007;
164(9):
1404 - 1410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al.
Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine
J. Pharmacol. Exp. Ther.,
December 1, 2005;
315(3):
1265 - 1277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Molitch
Medication-Induced Hyperprolactinemia
Mayo Clin. Proc.,
August 1, 2005;
80(8):
1050 - 1057.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. G Robinson, M. G Woerner, H. M Delman, and J. M Kane
Pharmacological Treatments for First-Episode Schizophrenia
Schizophr Bull,
July 1, 2005;
31(3):
705 - 722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Knegtering, P. Baselmans, S. Castelein, F. Bosker, R. Bruggeman, and R. J. van den Bosch
Predominant Role of the 9-Hydroxy Metabolite of Risperidone in Elevating Blood Prolactin Levels
Am J Psychiatry,
May 1, 2005;
162(5):
1010 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Dunkley and M. A. Reveley
Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma
J Psychopharmacol,
January 1, 2005;
19(1):
97 - 101.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al.
Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine
J Psychopharmacol,
September 1, 2004;
18(3):
355 - 365.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al.
Physical Health Monitoring of Patients With Schizophrenia
Am J Psychiatry,
August 1, 2004;
161(8):
1334 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mamo, S. Kapur, C. M. Shammi, G. Papatheodorou, S. Mann, F. Therrien, and G. Remington
A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone
Am J Psychiatry,
May 1, 2004;
161(5):
818 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Meaney and V. O'Keane
Reduced Bone Mineral Density in Patients with Schizophrenia Receiving Prolactin Raising Anti-Psychotic Medication
J Psychopharmacol,
December 1, 2003;
17(4):
455 - 458.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. E. Keck Jr., R. Marcus, S. Tourkodimitris, M. Ali, A. Liebeskind, A. Saha, G. Ingenito, and the Aripiprazole Study Group
A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania
Am J Psychiatry,
September 1, 2003;
160(9):
1651 - 1658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. ALEXIADIS, D. WHITEHORN, H. WOODLEY, and L. KOPALA
Prolactin Elevation With Quetiapine
Am J Psychiatry,
September 1, 2002;
159(9):
1608 - 1609.
[Full Text]
|
|
|
|
|
|
|
S. Kapur, X. Langlois, P. Vinken, A. A. H. P. Megens, R. De Coster, and J. S. Andrews
The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats
J. Pharmacol. Exp. Ther.,
September 1, 2002;
302(3):
1129 - 1134.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
TOP
Abstract
Introduction
